RareMed Solutions, a provider of patient support services for complex therapies, is expanding its relationship with PTC Therapeutics with the launch of non-commercial pharmacy dispensing services for PTC’s therapy, Sephience. The recent approval of Sephience by the FDA marks a significant milestone in the treatment of phenylketonuria (PKU) for both adult and pediatric patients. This new therapy, developed by PTC, has the potential to transform the lives of those living with PKU by offer...